Heart failure (HF) is a clinical syndrome characterized by the presence of dyspnea or limited
exertion due to impaired cardiac ventricular filling and/or blood ejection. Because of its high …

Despite significant therapeutic advances, patients with chronic heart failure (HF) remain at
high risk for HF progression and death. Sacubitril/valsartan (previously known as LCZ696) is …

Objective: To evaluate the clinical role of sacubitril/valsartan, a novel angiotensin–neprilysin
inhibitor, for the treatment of chronic heart failure with a reduced ejection fraction (HFrEF) …

Sacubitril/valsartan (S/V) is a pharmaceutical strategy that increases natriuretic peptide
levels by inhibiting neprilysin and regulating the renin-angiotensin-aldosterone pathway …

Sacubitril/valsartan is a first-in-class angiotensin receptor-neprilysin inhibitor (ARNI) that has
been recommended in clinical practice guidelines to reduce morbidity and mortality in …

Heart failure (HF) with preserved ejection fraction (HFpEF) is a clinical condition
characterized by large pathophysiology heterogeneity with lack of effective therapies as …

Sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor (ARNI), has been shown to
reduce the risk of cardiovascular death or heart failure hospitalization and improve …

Heart failure (HF) is one of the leading causes of morbidity and mortality worldwide.
Sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor, has been approved for the …

Heart failure is a global problem with elevated prevalence, and it is associated with
substantial cardiovascular morbidity and mortality. Treating heart-failure patients has been a …

With an estimated prevalence of 5.8 million in the USA and over 23 million people
worldwide, heart failure (HF) is growing in epidemic proportions. Despite the use of …